TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06361095

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Attention Bias Modification
Description: Each ABM trial begins with a central fixation cross for 1500ms, followed by a pair of POFA or IAPS stimuli (see Figure 3). POFA pairs will be presented for 3000ms, while IAPS pairs will be presented for 4500ms (due to the increased image complexity of IAPS images relative to POFA images). Longer stimulus duration times were selected based on evidence that attention biases for sad stimuli are prolonged in depression. Following offset of the images, either a single or double asterisk probe appears in the location of one of the images and will remain until a participant response or 10,000ms. In active ABM, the probe had an 80% probability of appearing in the location of the neutral stimulus. Investigators selected 80% rather than 100% to allow for computing attention bias during training and to facilitate task engagement. At the end of each ABM session, participants are provided feedback regarding their task performance relative to their last five sessions in a visual format.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified Attention Bias Modification
Description: Each trial consists of the fixation stage, facial cue stage, and response stage. At the fixation stage, an image appears (a colorful medallion) for 500 ms. The fixation appears randomly within a fixed rectangular field on the user's smartphone screen, and is always at the midpoint between the two face cues that will appear in the next stage. Next, after the cue disappears, two animated faces appear on the screen, one happy and one sad, with a 1000ms duration. Immediately after they disappear, a target probe (a trail) appears in the location of the happy face cue. The path remains (up to 3 seconds) until participants respond by tracing it starting from the point at which the face cue disappeared. They are instructed to quickly but accurately trace the path with their finger and receive visual and haptic feedback during tracing to indicate they are tracing accurately, followed by the path disappearing.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Attention Bias Modification
Description: Sham attention bias modification designed to match the active ABM condition in all respects except for the shifting attention away from negative stimuli in active attention bias modification.
Study: NCT05567939

Intervention type: OTHER
Intervention: Natural course of disease
Description: Sample and questionnaire collection

Intervention type: OTHER
Intervention: Natural course of disease
Description: Sample and questionnaire collection
Study: NCT06744868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THDBH120 injection (MAD)
Description: Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of THDBH120 injection (MAD)
Description: Participants received placebo once weekly for four weeks by subcutaneous injection.
Study: NCT06744036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Exercise
Description: The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Current
Description: However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee. The parameters used were as follows: carrier current frequency of 4000 Hz; amplitude modulated frequency of 50 Hz; sweep frequency of 50 Hz; oscillation pattern of 1:1 second, and the amplitude of the current will be increased until the research participants report strong but comfortable and non-painful stimulation paresthesia. The interferential current will be applied for 30 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo interferential current
Description: However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee. The parameters used were as follows: carrier current frequency of 4000 Hz; amplitude modulated frequency of 50 Hz; sweep frequency of 50 Hz; oscillation pattern of 1:1 second, and the amplitude of the current will be increased until the research participants report strong but comfortable and non-painful stimulation paresthesia. The device will only be turned on in the first minute
Study: NCT06740890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine-samidorphan + exercise
Description: 8 weeks of open label Olanzapine-samidorphan + 4 weeks of aerobic exercise
Study: NCT06744153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Space Maintainer
Description: Fabrication of KOS\&MET functional space maintainer and its cementation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Space Maintainer
Description: Fabrication of KOS\&MET functional space maintainer and its cementation.
Study: NCT06747130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast Placebo
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
Study: NCT06747078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy (NDT) + Core Stabilization Training
Description: In addition to the neurodevelopmental treatment of 30 minutes per day, 3 sessions per week, and a total of 24 sessions, core stabilization training was applied 3 sessions per week for 8 weeks and a total of 24 sessions. The core stabilization training session lasted 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental therapy + Balance Exercises
Description: In addition to NDT, which is 30 minutes per day, 3 sessions per week and 24 sessions in total, balance training was applied 3 sessions per week for 8 weeks and 24 sessions in total. The balance exercise session lasted 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental therapy
Description: NDT was applied for 60 minutes per day, 3 sessions per week, for 8 weeks and a total of 24 sessions.
Study: NCT06751043

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Process: Fasting pre-procedure~Tube feeding will be stopped at least 8 hours before the patient's scheduled surgery or procedure time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Not fasting
Description: Process: Not fasting pre-procedure~Tube feeding will be continued until patient transfer to the operating room/procedure area.
Study: NCT06629922

Intervention type: OTHER
Intervention: No intervention
Description: This is a observational study and the participants will not receive any intervention

Intervention type: OTHER
Intervention: No intervention
Description: This is a observational study and the participants will not receive any intervention
Study: NCT06221618

Intervention type: OTHER
Intervention: High-frequency carotid arteries ultrasound, CCTA, Cranial MRA
Description: CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines

Intervention type: OTHER
Intervention: High-frequency carotid arteries ultrasound, CCTA, Cranial MRA
Description: CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines

Intervention type: OTHER
Intervention: High-frequency carotid arteries ultrasound, CCTA, Cranial MRA
Description: CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines
Study: NCT05990517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YD01-2022
Description: Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
Study: NCT06750484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Participants will receive the study drug trastuzumab deruxtecan (T-DXd) by IV infusion every 21 days. The number of treatment cycles will depend on how participants respond to treatment.
Study: NCT06749002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Turning based specific training along with functional Muscle training
Description: Experimental group will receive Turning based specific training protocol for 6 weeks along with functional muscle training, training will be done on alternate days.~Functional muscle training:~Details: Week 1-6: 3 days a week on alternate days.~Hip Abductors:~Side lying leg raises Single leg squatting Standing leg wall press Progressing to Adding resistance bands~Hip adductors:~Side lying adduction Standing Adduction Progress to adding resistance bands~Hip Flexors:~Standing leg lift Straight leg raises Progress to adding resistance bands~Hip Extensors:~Prone lying raises Standing single leg extension Progress to adding resistance bands~Plantarflexors/ DorsiFlexors:~Plantarflexors:~Plantarflexion against resistance Toe raises~Dorsiflexors:~Dorsiflexion against resistance Heel raises~Hip external rotators:~Sitting-externally rotate hip 0-30° Add resistance bands~Hip Internal rotators:~Sitting-internally rotate the hip 0-30° Add resistance bands.
Study: NCT04886180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxiris membrane
Description: Hemofiltration treatment with Oxiris membrane connected to the ECLS circuit for 24 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prismaflex membrane
Description: Treatment by hemofiltration with PrismaFlex ST150 membrane connected to the ECLS circuit for 24 hours.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood tests
Description: Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
Study: NCT05674799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NDPP-NextGen
Description: NDPP-NextGen will incorporate content on preconception/prenatal health into standard NDPP. Participants will be encouraged to make sustainable improvements in diet and activity, but without pre-set goals to better accommodate diverse, low-income populations. Upon pregnancy, recommendations will adjust to support appropriate GWG, breastfeeding, and postpartum weight loss. We will provide education on diet and activity during pregnancy/postpartum, including sufficient energy intake and exercise safety to support the growing fetus. NDPP-NextGen will include 3 strategies to better engage young women. (1) Pre-sessions to increase knowledge of diabetes risks, self-efficacy, and readiness to change using motivational interviewing techniques. (2) Delivering classes remotely (via phone- and video-conference) to facilitate participation regardless of inclement weather, dependent care, illness, transportation, etc. (3) Offering classes specially for young women to increase personal relevance.
Study: NCT04944472

Intervention type: BEHAVIORAL
Intervention: HDKQ questionnaire
Description: Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram

Intervention type: BEHAVIORAL
Intervention: HDKQ questionnaire
Description: Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
Study: NCT04886180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood tests
Description: Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
Study: NCT05602857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: The BT program has multiple difficulty levels, and each child will progress at an individual pace tailored to their balance skills. Training sessions will emphasize top-down control of balance and contain a combination of dynamic and static balance exercises. Children and their parents will receive written step-by-step instructions, with photos, verbal and/or video instructions on their private OneDrive folder.~To monitor compliance, whether the exercises were done properly, and evaluate a child's progress, the parent/guardian will film the sessions, and upload the video to OneDrive, so we can score the child's performance and provide them with a progress tracking chart.~Every child will be given the equipment needed to do the balance exercises: two wooden beams that will make a 12-foot balance beam, four small wooden cubes that will raise the balance beam 5 inches off the ground, a wobble board, a hopscotch mat, one roll of painter's tape, one measuring tape, a bell, a small book.
Study: NCT06749002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: turning based specific training.
Description: Week 1:~90 Degrees turns on the spot~Visual cues to follow~Week 2-3:~90 degrees turns on the spot~Figure of 8 walking~Visual cues to follow~Week 4-5:~90 Degrees turns on the spot~Figure of 8 walking~Step across body~Braiding~Week 6:~90 degree turns on the spot~Figure of 8 walking~Step across body~Braiding~Visual cues to follow~Obstacle avoidance
Study: NCT06748534

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plus Lens Addition (+0.75 D)
Description: Participants in this group were provided with +0.75 D lenses, designed to assist in alleviating strain caused by accommodative infacility by reducing the demand on the eye's focusing mechanism.
Study: NCT05602857

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Training
Description: Children assigned to MT will be asked what kind of music and what performers they like best, and what songs they like most. After those open-ended questions, they will be asked about specific songs, guided somewhat by the child's previous answers, and will watch short excerpts from music videos to see which the child would like to listen to and watch during Week 1 of the MT program. This is all to guide the selection of music videos the child will enjoy and might give some thought to.~They will receive 10 music videos per week, through the child's private OneDrive folder, from which they can choose 4 to watch every session. Children will be instructed to not do anything else, but simply watch the videos or listen with their eyes closed.~To monitor compliance, and to check if the child was paying attention to the music videos or just having them play in the background while doing something else, the parent/guardian will film the MT sessions, and upload the video to OneDrive.
Study: NCT06375824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei Recipe
Description: Bufei Recipe: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bufei Recipe placebo
Description: The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
Study: NCT05817331

Intervention type: OTHER
Intervention: Carer Treatment Preference Myelodysplasia Questionnaire
Description: Caregiver-reported outcome measure in MDS

Intervention type: OTHER
Intervention: Clinician Treatment Preference Myelodysplasia Questionnaire
Description: Clinician-reported outcome measure in MDS
Study: NCT04944472

Intervention type: BEHAVIORAL
Intervention: HDKQ questionnaire
Description: Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
Study: NCT06495580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optic Nerve Stimulation
Description: Anterograde Stimulation of the Optic Neve.
Study: NCT01004315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC-7483
Study: NCT06748534

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Vision Therapy Using HART Chart
Description: Intervention Details: Participants in this group underwent vision therapy sessions utilizing the HART chart, aimed at enhancing their accommodative flexibility through repetitive focusing exercises.
Study: NCT06749704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: High protein diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal Protein diet
Description: Normal protein diet
Study: NCT06748872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepletion
Description: Cylcophosamide and Fludarabine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T cells (MDG1015)
Description: TCR-T cells (MDG1015)
Study: NCT06750081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Exercises to improve locomotor abilities of children with CP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed rehabilitation program
Description: Program of exercises to enhance abilities
Study: NCT05807334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH eating plan with eggs
Description: Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to eat 2 whole eggs per day to supplement the DASH eating pattern.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH eating plan without eggs
Description: Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to exclude eggs from their diet on a daily basis.
Study: NCT05275738

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide
Description: Study tablets for nicotinamide are produced by Blackmores Ltd.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study tablets for placebo are produced by Blackmores Ltd.
Study: NCT06749860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin + tislelizumab + bevacizumab
Description: Disitamab Vedotin, dosing regimen: 2.0 mg/kg, intravenous infusion, infusion should be about 30-90 minutes (usually about 60 minutes), every 21 days a cycle, the first day of administration, continuous use.~Tislelizumab, dosing regimen: 200 mg administered by intravenous infusion every 21 days in a cycle on the first day, continuous.~Bevacizumab, dosing regimen; 7.5 mg/kg administered by intravenous infusion every 21 days in a cycle on the first day of continuous use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin + tislelizumab + bevacizumab
Description: Disitamab Vedotin, dosing regimen: 2.0 mg/kg, intravenous infusion, infusion should be about 30-90 minutes (usually about 60 minutes), every 21 days a cycle, the first day of administration, continuous use.~Tislelizumab, dosing regimen: 200 mg administered by intravenous infusion every 21 days in a cycle on the first day, continuous.~Bevacizumab, dosing regimen; 7.5 mg/kg administered by intravenous infusion every 21 days in a cycle on the first day of continuous use.
Study: NCT04661930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TriCor® 145mg tablets
Description: Fenofibrate; 145 mg daily (1/day); oral administration; 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: All participants will otherwise receive usual medical care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: All participants will otherwise receive usual medical care
Study: NCT05872971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling: The technique will be used by a physiotherapist experienced in orthopedic conditions and with specific training in DN. The application will be through the deep technique, above 10mm deep, the therapist will score trigger points regions of the muscles of the posterolateral region of the hip with application duration of 30 to 60 seconds. Eight points of application will be standardized in the region of the muscles of the posterolateral region of the hip.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lasertherapy
Description: Lasertherapy: The application of the Laser will be performed by a physiotherapist specialized in traumato-orthopedics. The equipment will be infrared laser (904 nm), by point technique. Eight points of application will be standardized in the region of muscles of the posterolateral region of the hip. The time, dose and amounts of application points will be guided according to the dosimetry criteria of the World Association for Photobiomodulation Therapy.
Study: NCT05817331

Intervention type: OTHER
Intervention: Patient Treatment Preference Myelodysplasia Questionnaire
Description: Patient-reported outcome measure (PROM) in MDS